Libtayo Intravenous Infusion 350 mg Special Drug-use Results Survey for Cervical Cancer

Libtayo Intravenous Infusion 350 mg Special Drug-use Results Survey for Cervical Cancer - Libtayo Intravenous Infusion 350 mg Special Drug-use Results Survey for Cervical Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052336

Enrollment

120

Registered

2023-10-01

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent cervical cancer with disease progression after chemotherapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients newly treated with cemiplimab according to the dosage and administration of the drug for the approved indication of advanced or recurrent cervical cancer with disease progression after chemotherapy in Japan.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Incidence proportion of adverse drug reactions to safety specifications during the observation period	—

Countries

Japan

Contacts

Public ContactAyumi Emoto

Global Patient Safety Global Patient Safety

ayumi.emoto@regeneron.com09087250671

Outcome results